152 related articles for article (PubMed ID: 29019869)
1. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
3. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
4. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
5. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma.
Ma FH; Qiang JW; Zhang GF; Li HM; Cai SQ; Rao YM
J Ovarian Res; 2016 Jul; 9(1):40. PubMed ID: 27377917
[TBL] [Abstract][Full Text] [Related]
8. HNF-1β in ovarian carcinomas with serous and clear cell change.
DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
[TBL] [Abstract][Full Text] [Related]
9. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary.
Ota T; Clayton AC; Minot DM; Shridhar V; Hartmann LC; Gilks CB; Chien JR
Mod Pathol; 2011 Feb; 24(2):277-87. PubMed ID: 21076460
[TBL] [Abstract][Full Text] [Related]
10. Apparent diffusion coefficient (ADC) values of serous, endometrioid, and clear cell carcinoma of the ovary: pathological correlation.
Ono T; Kishimoto K; Tajima S; Maeda I; Takagi M; Suzuki N; Mimura H
Acta Radiol; 2020 Jul; 61(7):992-1000. PubMed ID: 31698924
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
[TBL] [Abstract][Full Text] [Related]
12. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Itamochi H; Kigawa J; Terakawa N
Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
16. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
[TBL] [Abstract][Full Text] [Related]
17. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
Miao Y; Cai B; Liu L; Yang Y; Wan X
Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
19. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
20. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
Liu P; Sun YL; Du J; Hou XS; Meng H
Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]